Amarin Corp Plc (AMRN)

[BaaBaa45]

The complaint alleged that concentrated omega-3 products sold in the US as dietary supplements are not in fact “dietary supplements” under the FD&C Act, but instead, are “unapproved new drugs.”2 Therefore, according to Amarin, the “false labeling” of these products unfairly competes with Vascepa, constituting “an unfair act and/or unfair method of competition under Section 337 because, among other things, these acts violate Section 43(a) of the Lanham Act, 15 USC 1125(a) and the standards established by the FD&C Act.

ok, so not so much the medical use point - more nuanced than that....

https://www.raps.org/news-and-articles/news-articles/2018/7/update-on-the-amarin-itc-case-and-the-issues-at-st